PharmaFocus Today – Page 17 – media

Twinings Biopharmaceuticals, Lingrui, Hisun…

As of the first three quarters, there were 9 pharmaceutical stocks with a market value of 100 billion yuan, with Mindray Medical firmly in the top spot and Hengrui Medicine returning to a market value of 300 billion yuan. In terms of quantity, there were 4 more stocks compared with the first half of the year, with Aier Eye Hospital, Yunnan Baiyao, United Imaging Healthcare, and Wantai Biopharma returning to the 100 billion yuan market value echelon. Among the TOP20, 15 stocks have positive growth, with Hengrui Medicine, BeiGene, Yunnan Baiyao, Shanghai Pharmaceuticals, China Resources Sanjiu, Baili Tianheng and 10 other stocks growing at a rate of more than 10%; while in the first half of the year, only 6 stocks had positive growth, with 4 other stocks growing at a rate of more than 10%, including Shanghai Pharmaceuticals and China Resources Sanjiu. Mindray Medical has firmly established itself as ...
- Source: drugdu
- 73
- October 12, 2024
New president of Beckman takes office

Recently, according to the official website of Beckman Coulter Life Sciences, Danaher subsidiary Beckman Coulter Life Sciences (hereinafter referred to as Beckman) announced the appointment of Joe Fox as president, effective immediately. It is understood that Joe Fox is a veteran of Danaher. He served as president of Danaher subsidiary Sciex, and before becoming president, he held several leadership positions in the company, including senior vice president of global sales and services. In 13 years, Joe Fox has held positions with increasing responsibilities until he became president recently. Before joining Sciex, Joe Fox held technical and commercial positions at Bruker and Shimadzu, and Joe Fox also holds a degree in biochemistry from the University of Delaware and a doctorate in chemistry from Johns Hopkins University. After taking office, Joe Fox will lead a global team of more than 3,300 employees to promote product and service innovation to provide solutions in ...
- Source: drugdu
- 71
- October 12, 2024
A major pharmaceutical province issued a document to dig deep into medical corruption

In May this year, the National Health Commission and 14 other departments issued the “Notice on Printing and Distributing the Key Points for Correcting Unhealthy Trends in the Field of Pharmaceutical Purchase and Sale and Medical Services in 2024”, which includes 5 parts and 15 items. The local level has also successively issued the key points for correcting unhealthy trends in 2024. Judging from the above-mentioned “Notice” issued by Shanghai, the key points for Shanghai’s corrective work in 2024 are basically consistent with the national documents, and some new content has also been added, totaling 5 parts and 18 items. The “Notice” clearly states that the city’s centralized rectification of corruption in the pharmaceutical field and the centralized rectification of unhealthy trends and corruption around the masses should be carried out in a coordinated manner, and the construction of systems in the field of pharmaceutical purchase and sale should be ...
- Source: drugdu
- 75
- October 12, 2024
Drugdu.com Shines at CPhI Milan 2024

▲October 2024, CPhI Milan On October 10, 2024, the highly anticipated CPhI Milan event concluded in Italy, leaving behind a lasting impression. Drugdu.com, a global leader in cross-border pharmaceutical B2B platforms, stood out with its innovative digital solutions and accurate buyer-supplier matching services, garnering widespread attention from the global pharmaceutical community. ▲Drugdu.com at the CPhI Milan show in October 2024 Platform Highlights: Smart Cross-Border Trade Services At the event, Drugdu.com demonstrated its leading smart supply-demand matching feature, allowing buyers to effortlessly post procurement needs and swiftly connect with high-quality global suppliers. The platform’s real-time, efficient negotiations boosted transaction success, with many participants leveraging its capabilities to finalize collaborations during the exhibition. Additionally, Drugdu.com provided VIP members with customized promotion strategies, offering exclusive brand exposure and diverse inquiry channels to help businesses expand their global market presence. Advancing Digital Pharmaceutical Trade Beyond being a platform, Drugdu.com is committed to advancing the digitalization ...
- Source: drugdu
- 71
- October 11, 2024
intensified BD trading competition in the pharmaceutical market, pharmaceutical companies launch market competition war

October 11, 2024 09:03 Source: 21st Century Business Herald Has the cow arrived? The A-share market is booming, don’t miss the opportunity, open an account and layout now>> Recently, there has been a frequent wave of business development (BD) cooperation transactions between Chinese and foreign pharmaceutical companies. On October 9th, Baiaotai announced that it has reached an authorization license, production, supply, and commercialization agreement with Gedeon Richter Plc. for BAT2206 (ustekinumab) injection solution. According to the agreement, Baiaotai will license the exclusive commercial rights of the injection in the EU, UK, Switzerland, Australia, and other European markets to Gedeon Richter Plc for a fee. The amount involved in this transaction includes a down payment of $8.5 million, milestone payments up to a cumulative total of $101.5 million, and revenue sharing based on a double-digit percentage of net sales. In addition to Baiaotai, several Chinese pharmaceutical companies have also recently received ...
- Source: drugdu
- 78
- October 11, 2024
Beckman’s new president takes office

Recently, according to the official website of Beckman Coulter Life Sciences, a subsidiary of Danaher, Beckman Coulter Life Sciences announced the appointment of Joe Fox as President, effective immediately. Following the promotion of Chen Xiaoxiao, former General Manager of Beckman Clinical Diagnostics China, to President of Danaher China Medical Diagnostic Platform in the first half of the year, Beckman has once again announced personnel changes. It is understood that Joe Fox is a veteran of Danaher and has served as the president of Danaher’s subsidiary, Sciex. Prior to becoming president, he held multiple leadership positions at the company, including Senior Vice President of Global Sales and Service. Over the course of 13 years, Joe Fox’s responsibilities have increased, until he recently became president. Prior to joining Sciex, Joe Fox held technical and business positions at Bruker and Shimadzu, and also holds a Bachelor of Science degree in Biochemistry from the ...
- Source: drugdu
- 72
- October 11, 2024
Domestic PD-1 accelerates landing in Europe and America! Junshi and Baekje are rushing to the beach, and the next one is Hengrui?

Recently, BeiGene announced that its PD-1 inhibitor Trastuzumab (US trade name: TEVIMBRA) has been officially commercialized in the United States for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously received systemic chemotherapy (excluding PD-1/L1 inhibitors). Global pharmaceutical companies consider the US market as a battleground for going global. At the end of October 2023, Junshi Biotech’s trastuzumab (US trade name: LOQTORZI) obtained FDA approval, becoming the first nasopharyngeal carcinoma drug to be marketed in the United States, as well as the first biologically innovative drug and PD-1 inhibitor from China approved by the FDA. In March 2024, BeiGene’s Trastuzumab was approved for its first indication in the United States, following closely behind. After more than six months of FDA approval, Trastuzumab has finally been officially launched for sale in the United States. In the industry’s view, Chinese pharmaceutical companies such as ...
- Source: drugdu
- 62
- October 11, 2024
Another new analgesic has been submitted for marketing application

Vertex (Futai Pharmaceuticals) has a long-standing reputation. It has worked in the field of rare diseases for more than ten years and has created an orphan drug blockbuster trikafta with annual sales of over $10 billion. Today, the company has opened up new horizons in another field. Recently, Vertex announced that the FDA has accepted the marketing application of the Nav1.8 inhibitor VX-548 (Suzetrigine) and granted priority review qualification for the treatment of moderate to severe acute pain. This is a major breakthrough in the field of analgesics and may subvert the competitive landscape of analgesics commercialization. Analgesics have always been valued by the medical community, both in academia and industry. And every pharmacology textbook and medicinal chemistry textbook used as a teaching material cannot avoid a classic drug: morphine. Whether it is its rigid structure of five fused rings or its analgesic and antitussive pharmacological effects, it is well ...
- Source: drugdu
- 67
- October 11, 2024
Over $440 million! Jiahe Biologics’ new dual-antibody drug goes overseas

On August 5, Hong Kong-listed innovative pharmaceutical company Jiahe Biologics (06998.HK) announced that the group entered into a licensing agreement and equity agreement with TRC2004, Inc. on August 2. Pursuant to the License Agreement, the Group has agreed, among other things, to grant TRC2004 an exclusive global license (excluding Mainland China, Hong Kong, Macau and Taiwan) to develop, use, manufacture, commercialize and otherwise exploit GB261. According to the terms of the license agreement and equity agreement, as consideration for the license, the Group will receive a considerable amount of equity in TRC2004, an down payment of tens of millions of US dollars, milestone payments of up to US$443 million, and a single-digit to double-digit share of net sales. percentage tiered royalties. CD3/CD20 inhibitor potential stocks. GB261 is a new type of differentiated CD20/CD3 bispecific T cell engager (TCE) and the first T cell engager (T-cell Engager) that binds to CD3 ...
- Source: drugdu
- 61
- October 11, 2024
A large number of zombie approvals are facing “cleaning”?

On September 3, 2024, the Yunnan Provincial Drug Administration issued the “Notice on Further Strengthening the Supervision and Management of Drug Entrusted Production”, which clearly stated: “Applications without a drug GMP compliance inspection notice and consent to entrusted production issued by the provincial drug regulatory department where the entrusted enterprise is located will not be accepted; in principle, applications for long-term unproduced varieties that do not meet the conditions for resuming production will not be accepted.” This means that if the “zombie approval” that has not been produced for a long time is not resumed at the original factory, it will be difficult for the transferee to obtain a B certificate, that is, Yunnan enterprises basically cannot buy approvals that have not been produced for a long time. It seems that the regulatory authorities are worried about the resumption of sales of products whose generic names have not been produced ...
- Source: drugdu
- 59
- October 11, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.